In this episode, 340B Report Associate Editors and Senior Writers Shannon Young and Will Newton and National Correspondent Luke Zarzecki break down the latest in 340B news, including the wave of identical responses to the Health Resources and Services Administration's (HRSA) 340B rebate request for information (RFI), the Trump Administration's renewed proposal to shift oversight of the 340B program to another federal agency and key legal developments with major 340B implications.

Key Topics Covered:

Duplicate 340B Rebate RFI Responses

Will breaks down early stakeholder responses to the HRSA's 340B rebate RFI, which the agency issued just days after withdrawing its previous 340B rebate pilot. He notes that more than half of the initial responses were identical submissions closely mirroring a template from Patients Rising, a patient group that lists more than a dozen large drugmakers among its corporate sponsors. Will notes that hours after 340B Report broke news on the submissions, Patients Rising said it was ending work with the third-party firm it hired for RFI outreach.

Trump's New Budget and Tariffs

Shannon discusses the Trump administration's proposed fiscal year (FY) 2027 Health and Human Services Department budget and what it means for the 340B program. She notes that the HHS spending proposal revives previous plans to restructure HRSA and move the 340B program to the Centers for Medicare and Medicaid Services, as well as calls for a major increase in 340B funding. Luke offers insights into how Congress could approach FY 27 funding legislation—including an effort to attach language barring a 340B rebate model. Luke also breaks down the White House's latest plans to implement tariffs on pharmaceutical products.

Key Legal Developments

Shannon discusses the implications of a recent Washington, D.C. federal district court ruling that struck down a 2013 HRSA policy that restricts how certain 340B hospitals can purchase initial drug inventory. Will breaks down drugmaker AbbVie's new lawsuit challenging HRSA's 340B patient definition, including the history of the agency's definition and what the legal outcome could mean for the 340B program's future.

Subscribe & Stay Updated

How to Follow Us and Learn More About This Episode's Sponsor

Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.

Each episode is brought to you by one of our great Ultra Diamond sponsors. PharmaForce is the only third party administrator composed entirely of experienced 340B professionals developing uniquely flexible technology solutions for covered entities and pharmacies of every size. Learn more at www.thepharmaforce.com. We are very grateful to PharmaForce for its sponsorship.

Subscribe to 340B Report with a Special Discount

We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.